Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.58 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.57 |
| ▸ | VEGFA | P15692 | 2/20 | 0.46 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | BPTF | Q12830 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21751214 | 1.00 | ADRB2 (0.58) | ADRB2ADRA2ACX3CR1VEGFAEGLN1 | |
| SCHEMBL20551971 | 0.82 | ADRB2 (0.53) | ADRB2ADRA2ACX3CR1OPRK1MAPT | |
| SCHEMBL20551988 | 0.78 | ADRB2 (0.56) | ADRB2ADRA2ACX3CR1OPRK1OPRM1 | |
| SCHEMBL20552914 | 0.78 | DRD4 (0.50) | ADRB2ADRA2ACX3CR1OPRK1MAPT | |
| SCHEMBL6846822 | 0.78 | HTR7 (0.65) | OPRK1OPRM1 | |
| SCHEMBL20551968 | 0.78 | ADRB2 (0.55) | ADRB2ADRA2ACX3CR1OPRK1OPRM1 | |
| SCHEMBL21751224 | 0.77 | ADRA2A (0.52) | ADRB2ADRA2ACX3CR1OPRK1THRB | |
| SCHEMBL20553531 | 0.76 | OPRK1 (0.58) | ADRB2ADRA2ACX3CR1OPRK1THRB | |
| SCHEMBL20553530 | 0.76 | ADRB2 (0.56) | ADRB2ADRA2ACX3CR1OPRK1MAPT | |
| SCHEMBL21751222 | 0.74 | OPRM1 (0.54) | ADRB2ADRA2ACX3CR1OPRK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11267817-B2 | Substituted pyrrolo[1,2-a]quinoxalin-4(5H)-ones as CX3CR1 antagonists | DREXEL UNIVERSITY (US) | 2022-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11267817-B2 | Substituted pyrrolo[1,2-a]quinoxalin-4(5H)-ones as CX3CR1 antagonists | CX3CR1, CCR5, CCL2 | ADRB2 597/4885ADRA2A 591/4885CX3CR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.